Memabix (Memantine Hydrochloride)

Memantine works by blocking the NMDA receptor’s ion channel in a non‑competitive manner. This reduces excessive calcium influx caused by over‑activation of glutamate pathways, protecting neurons from excitotoxic damage while allowing normal synaptic activity to continue.

The appropriate dose of Memabix is determined by the prescribing healthcare professional based on the patient’s condition, age, renal function and other factors. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memabix (memantine) belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine targets glutamatergic excitotoxicity, offering a different mechanism that can be used alone or in combination with cholinesterase inhibitors for additive benefit.

Memabix should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Memabix is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious adverse events, though rare, can include seizures, severe psychiatric reactions such as hallucinations or suicidal thoughts, cardiac arrhythmias, and significant liver injury. Patients should be monitored closely for any new or worsening symptoms and seek medical attention promptly if they occur.

Memabix is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal or hepatic impairment, uncontrolled cardiovascular disease, or those taking other NMDA antagonists, as the risk of adverse effects may be heightened.